Directorate Change

RNS Number:9745T
CeNeS Pharmaceuticals PLC
08 January 2004


      CeNeS announces appointment of Alan Smith as non-executive director

Cambridge, UK, 8th January 2004 - CeNeS Pharmaceuticals plc (LSE: CEN) ("CeNeS"
or "the Company") today announced the appointment of Alan Smith as a
non-executive director of CeNeS Pharmaceuticals plc. Alan Smith has had
extensive experience at senior executive and non-executive level in listed
companies and is currently Chairman of Acambis plc and Avlar Bioventures
Limited.

Commenting on the appointment, Alan Goodman, Chairman of CeNeS said, "I am
delighted to welcome Alan Smith to the CeNeS Board. His experience of
successfully growing a biotechnology company combined with his general listed
company expertise will be of great value to CeNeS. This appointment is also
another step forward for CeNeS as the company progresses its corporate
development. The Board believe that CeNeS is well positioned to deliver value to
shareholders in the future."

For more information please contact:

CeNeS Pharmaceuticals plc

Neil Clark

Tel: [phone]

Fax: [phone]


Capital MS & L

Mary Clark

Tel: [phone]

Fax: [phone]


Notes to Editors:

CeNeS is a biopharmaceutical company specialising in the discovery, development
and commercialisation of drugs for the treatment of pain and disorders of the
central nervous system. The company is based in Cambridge, England. For further
information visit www.cenes.co.uk .

Alan Smith, 58, is a member of the Chartered Institute of Public Finance and
Accountancy He joined the Board of Acambis plc on 3 November 1995 as a
non-executive Director and was appointed non-executive Chairman on 20 May 1999.
He was Group Managing Director of Anglian Water plc until December 1997 and is
currently Chairman of Avlar Bioventures Limited. Avlar Bioventures Limited
manages Avlar Bioventures Fund II Limited Partnership which has an interest in
22,786, 596 ordinary 1 pence shares in the Company representing 9.1 per cent of
the current issued share capital of the Company.

CeNeS confirms there are no other details to be disclosed under paragraph (f) of
Schedule 2 of the AIM rules in relation to the appointment of Alan Smith.







                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
BOAUUUMAGUPCGQM